3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Breast Neoplasms
5
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Ovarian Neoplasms
2
Neoplasms, Unknown Primary
2
Lung Neoplasms
2
Carcinoma
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Unresectable Stage III NSCLC
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Salivary Gland Neoplasms
1
Penile Neoplasms
1
Pathologic Complete Response
1
Ovarian Diseases
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Male Urogenital Diseases
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
First-line Advanced NSCLC Patients
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Endocrine System Diseases
1
Interventions
pembrolizumab
4
Nivolumab
4
fludarabine
3
aldesleukin
3
Paclitaxel
3
Ipilimumab
3
Cyclophosphamide
3
Carboplatin
3
padeliporfin
2
atezolizumab
2
anlotinib
2
Riluzole
2
Gemcitabine
2
vinflunine
1
sipuleucel-T
1
relatlimab
1
palbociclib
1
olaparib
1
niraparib
1
motexafin gadolinium
1
luprolide acetate gel depot
1
lenvatinib
1
ixabepilone
1
cabozantinib
1
Therapeutics
1
Suspensions
1
Surveys and Questionnaires
1
Sunitinib
1
Specimen Handling
1
Powders
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Urogenital Neoplasms
×
CP protocol
×
Clear all
NCT06353906
2025-12-08
PRIAM
The Netherlands Cancer Institute
Phase 2
Recruiting
27 enrolled